Artykuły w czasopismach na temat „BRCA testing”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „BRCA testing”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Parikh, Purvish M., J. Wadhwa, S. Minhas, A. Gupta, S. Mittal, S. Ranjan, P. Mehta i in. "Practical consensus recommendation on when to do BRCA testing". South Asian Journal of Cancer 07, nr 02 (kwiecień 2018): 106. http://dx.doi.org/10.4103/sajc.sajc_112_18.
Pełny tekst źródłaSahnane, Nora, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro i in. "BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor". International Journal of Molecular Sciences 21, nr 24 (19.12.2020): 9708. http://dx.doi.org/10.3390/ijms21249708.
Pełny tekst źródłaMoore, H. C., R. Wesolowski, T. K. Choueiri, L. Rybicki, A. G. Shealy, G. Casey i D. Weng. "Therapeutic radiation for breast cancer in BRCA mutation carriers and contralateral breast cancer (CBC) risk". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 611. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.611.
Pełny tekst źródłaBrankovic-Magic, Mirjana, Jelena Dobricic, Radmila Jankovic, Irene Konstantopoulou, Drakoulis Yannoukakos i Sinisa Radulovic. "Identifying and testing for hereditary susceptibility to breast/ovarian cancer in Serbia: Where are we now?" Archive of Oncology 14, nr 3-4 (2006): 131–35. http://dx.doi.org/10.2298/aoo0604131b.
Pełny tekst źródłaSchwartz, Zachary Phillip, Mae Zakhour, Andrew John Li, Christine S. Walsh, Bj Rimel, Monica Alvarado, Scott E. Lentz i Ilana Cass. "Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 1547. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1547.
Pełny tekst źródłaHolter, Spring, Ayelet Borgida, Anna Dodd, Robert Grant, Kara Semotiuk, David Hedley, Neesha Dhani i in. "Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma". Journal of Clinical Oncology 33, nr 28 (1.10.2015): 3124–29. http://dx.doi.org/10.1200/jco.2014.59.7401.
Pełny tekst źródłaToss, Angela, Eleonora Molinaro, Marta Venturelli, Federica Domati, Luigi Marcheselli, Simonetta Piana, Elena Barbieri i in. "BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy". Cancers 12, nr 5 (15.05.2020): 1252. http://dx.doi.org/10.3390/cancers12051252.
Pełny tekst źródłaShatavi, Seerin Viviane, Lindsay Dohany, Mohammad Muhsin Chisti, Ishmael A. Jaiyesimi i Dana Zakalik. "Unique genetic characteristics of BRCA mutation carriers in a cohort of Arab American women." Journal of Clinical Oncology 31, nr 15_suppl (20.05.2013): 1541. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1541.
Pełny tekst źródłaMatsubara, Nobuaki, Johann S. De Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yuksel Urun, Robbert J. van Alphen i in. "Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study." Journal of Clinical Oncology 39, nr 6_suppl (20.02.2021): 27. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.27.
Pełny tekst źródłaMurciano-Goroff, Yonina R., Alison M. Schram, Ezra Rosen, Yelena Y. Janjigian, Michael F. Berger, Mark Donoghue, Chaitanya Bandlamudi i Alexander E. Drilon. "BRCA reversion mutations in a pan-cancer cohort to reveal BRCA-dependence in select noncanonical BRCA-mutant histologies." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 3012. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3012.
Pełny tekst źródłaSekine, Masayuki, Koji Nishino i Takayuki Enomoto. "Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location". Genes 12, nr 7 (8.07.2021): 1050. http://dx.doi.org/10.3390/genes12071050.
Pełny tekst źródłaRahman, Belinda, Anne Lanceley, Rebecca S. Kristeleit, Jonathan A. Ledermann, Michelle Lockley, Mary McCormack, Tim Mould i Lucy Side. "Mainstreamed genetic testing for women with ovarian cancer: first-year experience". Journal of Medical Genetics 56, nr 3 (13.03.2018): 195–98. http://dx.doi.org/10.1136/jmedgenet-2017-105140.
Pełny tekst źródłaKapoor, Nimmi S., Lisa D. Curcio, Carlee A. Blakemore, Amy K. Bremner, Rachel E. McFarland, John G. West i Kimberly C. Banks. "Benefits and safety of multigene panel testing in patients at risk for hereditary breast cancer." Journal of Clinical Oncology 33, nr 28_suppl (1.10.2015): 16. http://dx.doi.org/10.1200/jco.2015.33.28_suppl.16.
Pełny tekst źródłaTrainer, Alison H., Bettina Meiser, Kaaren Watts, Gillian Mitchell, Kathy Tucker i Michael Friedlander. "Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer". International Journal of Gynecologic Cancer 20, nr 5 (czerwiec 2010): 704–16. http://dx.doi.org/10.1111/igc.0b013e3181dbd1a5.
Pełny tekst źródłaSalo-Mullen, Erin E., Eileen Mary O'Reilly, David Paul Kelsen, Maeve Aine Lowery, Kenneth H. Yu, Rohini Rau-Murthy, Beth Siegel i in. "Identification of germline genetic mutations in patients with pancreatic adenocarcinoma." Journal of Clinical Oncology 31, nr 4_suppl (1.02.2013): 159. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.159.
Pełny tekst źródłaImyanitov, Yevgeniy, Aleksey Belyaev, Aleksandr Shcherbakov, Lev Bershteyn, Aleksandr Bessonov, Petr Krivorotko, Tatyana Gorodnova i in. "PRESENCE OF BRCA1 AND BRCA2 IN HEALTHY WOMEN AND MEN: DNA TESTING, DIAGNOSTIC ACTIVITIES AND CANCER PREVENTION". Problems in oncology 63, nr 2 (1.02.2017): 190–98. http://dx.doi.org/10.37469/0507-3758-2017-63-2-190-198.
Pełny tekst źródłaJung, J., E. Kang, J. M. Gwak, A. N. Seo, S. Y. Park, A. S. Lee, H. Baek, S. Chae, E. K. Kim i S. W. Kim. "Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients". Current Oncology 23, nr 5 (26.10.2016): 298. http://dx.doi.org/10.3747/co.23.3054.
Pełny tekst źródłaMullai, N. "The importance of variants of unknown significance (VUS) in BRCA mutation." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e22507-e22507. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e22507.
Pełny tekst źródłaAtchley, Deann P., Constance T. Albarracin, Adriana Lopez, Vicente Valero, Christopher I. Amos, Ana Maria Gonzalez-Angulo, Gabriel N. Hortobagyi i Banu K. Arun. "Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer". Journal of Clinical Oncology 26, nr 26 (10.09.2008): 4282–88. http://dx.doi.org/10.1200/jco.2008.16.6231.
Pełny tekst źródłaNeveling, Kornelia, Arjen R. Mensenkamp, Ronny Derks, Michael Kwint, Hicham Ouchene, Marloes Steehouwer, Bart van Lier i in. "BRCA Testing by Single-Molecule Molecular Inversion Probes". Clinical Chemistry 63, nr 2 (1.02.2017): 503–12. http://dx.doi.org/10.1373/clinchem.2016.263897.
Pełny tekst źródłaLiu, Ying L., Julia Lindsay Boland, Karen Anne Cadoo, Claire Frances Friedman, Jason A. Konner, Roisin Eilish O'Cearbhaill, Carol Aghajanian i Dmitriy Zamarin. "Response to immune checkpoint inhibition and survival in BRCA-associated recurrent ovarian cancer." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 2615. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2615.
Pełny tekst źródłaSpizzo, Gilbert, Alberto Puccini, Joanne Xiu, Richard M. Goldberg, Axel Grothey, Anthony Frank Shields, Sukeshi Patel Arora i in. "Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI)." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 4085. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4085.
Pełny tekst źródłaOktay, Kutluk, Ja Yeon Kim, David Barad i Samir N. Babayev. "Association of BRCA1 Mutations With Occult Primary Ovarian Insufficiency: A Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks". Journal of Clinical Oncology 28, nr 2 (10.01.2010): 240–44. http://dx.doi.org/10.1200/jco.2009.24.2057.
Pełny tekst źródłaArun, Banu, Angelica Gutierrez Barrera, Rachel M. Layman, Stephen K. Gruschkus, Isabelle Bedrosian, Constance T. Albarracin, Carlos Hernando Barcenas, Vicente Valero, Jennifer Keating Litton i Debu Tripathy. "Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 1544. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1544.
Pełny tekst źródłaAkaev, Iolia, Siavash Rahimi, Olubukola Onifade, Francis John Edward Gardner, David Castells-Rufas, Eleanor Jones, Shyamika Acharige i Chit Cheng Yeoh. "Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom". Diagnostics 11, nr 3 (19.03.2021): 547. http://dx.doi.org/10.3390/diagnostics11030547.
Pełny tekst źródłaSmith, Wesley, Kayla Smith, William Sessions, Connor Evins, Michael Baker i Mary Blumer. "An evaluation of gender discrepancies in genetic referrals for BRCA testing for indicated malignancies." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 10584. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.10584.
Pełny tekst źródłaOktay, K., J. Kim, D. Barad, N. Gleicher i S. Babayev. "Association of BRCA1 mutations with diminished ovarian reserve: A common genetic mechanism for breast/ovarian cancer, and infertility?" Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): 11039. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11039.
Pełny tekst źródłaMetcalfe, Kelly A., Aletta Poll, Robert Royer, Marcia Llacuachaqui, Anna Tulman, Ping Sun i Steven A. Narod. "Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women". Journal of Clinical Oncology 28, nr 3 (20.01.2010): 387–91. http://dx.doi.org/10.1200/jco.2009.25.0712.
Pełny tekst źródłaLindsey, Heather. "BRCA Testing". Oncology Times 26, nr 3 (luty 2004): 12. http://dx.doi.org/10.1097/01.cot.0000291728.63654.be.
Pełny tekst źródłaMirza, M. A., A. Sehbai, T. Nestor, V. Brown i J. Abraham. "BRCA mutations: An Appalachian experience". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 20111. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.20111.
Pełny tekst źródłaPoon, Kok-Siong, Lily Chiu i Karen Mei-Ling Tan. "Laboratory Verification of a BRCA1 and BRCA2 Massively Parallel Sequencing Assay from Wet Bench to Bioinformatics for Germline DNA Analysis". Global Medical Genetics 08, nr 02 (16.03.2021): 062–68. http://dx.doi.org/10.1055/s-0041-1726338.
Pełny tekst źródłaHwang, E. Shelley, Jane L. McLennan, Dan H. Moore, Beth B. Crawford, Laura J. Esserman i John L. Ziegler. "Ductal Carcinoma In Situ in BRCA Mutation Carriers". Journal of Clinical Oncology 25, nr 6 (9.02.2007): 642–47. http://dx.doi.org/10.1200/jco.2005.04.0345.
Pełny tekst źródłaKeung, Yi-Kong, Adriana Hu, Annie Yeung, Amy Chan i Eddie Hu. "Higher prevalence of BRCA2 mutations among Chinese breast cancer patients in a community oncology clinic." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): e12017-e12017. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e12017.
Pełny tekst źródłaRandall, Megan, Kelly Burgess, Lela Buckingham i Lydia Usha. "Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion". Journal of the National Comprehensive Cancer Network 18, nr 3 (marzec 2020): 223–28. http://dx.doi.org/10.6004/jnccn.2019.7378.
Pełny tekst źródłaArun, Banu, Soley Bayraktar, Diane D. Liu, Angelica M. Gutierrez Barrera, Deann Atchley, Lajos Pusztai, Jennifer Keating Litton i in. "Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience". Journal of Clinical Oncology 29, nr 28 (1.10.2011): 3739–46. http://dx.doi.org/10.1200/jco.2011.35.2682.
Pełny tekst źródłaManchanda, Ranjit, Li Sun, Shreeya Patel, Olivia Evans, Janneke Wilschut, Ana Carolina De Freitas Lopes, Faiza Gaba i in. "Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems". Cancers 12, nr 7 (17.07.2020): 1929. http://dx.doi.org/10.3390/cancers12071929.
Pełny tekst źródłaWeitzel, Jeffrey N., Jessica Clague, Arelis Martir-Negron, Raquel Ogaz, Josef Herzog, Charité Ricker, Chelsy Jungbluth i in. "Prevalence and Type ofBRCAMutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network". Journal of Clinical Oncology 31, nr 2 (10.01.2013): 210–16. http://dx.doi.org/10.1200/jco.2011.41.0027.
Pełny tekst źródłaHowarth, Dt R., Sharon S. Lum, Pamela Esquivel, Carlos A. Garberoglio, Maheswari Senthil i Naveenraj L. Solomon. "Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome". American Surgeon 81, nr 10 (październik 2015): 941–44. http://dx.doi.org/10.1177/000313481508101006.
Pełny tekst źródłaChandrasekaran, Dhivya, Monika Sobocan, Oleg Blyuss, Rowan E. Miller, Olivia Evans, Shanthini M. Crusz, Tina Mills-Baldock i in. "Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study". Cancers 13, nr 17 (27.08.2021): 4344. http://dx.doi.org/10.3390/cancers13174344.
Pełny tekst źródłaMetcalfe, Kelly A., Aletta Poll, Andrea Eisen, Jordan Lerner-Ellis i Steven Narod. "Outcomes associated with rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 1577. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1577.
Pełny tekst źródłaAbida, Wassim, David Campbell, Akash Patnaik, Brieuc Sautois, Jeremy David Shapiro, Nicholas J. Vogelzang, Alan Haruo Bryce i in. "Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with BRCA1 or BRCA2 (BRCA)-mutated metastatic castration-resistant prostate cancer (mCRPC)." Journal of Clinical Oncology 38, nr 6_suppl (20.02.2020): 178. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.178.
Pełny tekst źródłaPal, Tuya, Deborah Cragun, Xuefeng Wang, Sean J. Yoder, Tania MESA, Marilin Rosa, Ann Tezak, Anne Weidner, Susan Thomas Vadaparampil i Catherine Phelan. "Characterization of germline and tumor genomic profile in unselected young black breast cancer patients." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): e13090-e13090. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13090.
Pełny tekst źródłaBahsi, Taha, i Haktan Bağış Erdem. "Spectrum of BRCA1/BRCA2 variants in 1419 Turkish breast and ovarian cancer patients: a single center study". Turkish Journal of Biochemistry 45, nr 1 (24.12.2019): 83–90. http://dx.doi.org/10.1515/tjb-2019-0424.
Pełny tekst źródłaGoncalves, Susana Beatriz, Gonzalo Giornelli, Marcelo Horacio Pereira, Dolores Gallardo-Rincon i Maria Del Pilar Estevez-Diz. "FLABRA, frontline approach for BRCA testing in ovarian cancer (OC) treatment naïve population: A Latin America (LA) epidemiologic study." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): e17050-e17050. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e17050.
Pełny tekst źródłaAbida, Wassim, Alan Haruo Bryce, Nicholas J. Vogelzang, Robert J. Amato, Ivor John Percent, Jeremy David Shapiro, Raymond S. McDermott i in. "Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2." Journal of Clinical Oncology 37, nr 15_suppl (20.05.2019): 5031. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.5031.
Pełny tekst źródłaToss, Angela, Marta Venturelli, Eleonora Molinaro, Stefania Pipitone, Elena Barbieri, Isabella Marchi, Elena Tenedini i in. "Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies". Cancers 11, nr 2 (7.02.2019): 193. http://dx.doi.org/10.3390/cancers11020193.
Pełny tekst źródłaDi Brino, Eugenio, Matteo Ruggeri, Stefania Boccia, Nicoletta Cerana, Domenica Lorusso, Dario Sacchini, Antonella Savarese, Liliana Varesco i Americo Cicchetti. "A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer". Global & Regional Health Technology Assessment 7, nr 1 (4.04.2020): 1–8. http://dx.doi.org/10.33393/grhta.2020.557.
Pełny tekst źródłaLipton, Joseph H., Mahdi Zargar, Ellen Warner, Ellen E. Greenblatt, Esther Lee, Kelvin K. W. Chan i William W. L. Wong. "Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations". Human Reproduction 35, nr 2 (luty 2020): 434–45. http://dx.doi.org/10.1093/humrep/dez203.
Pełny tekst źródłaSpizzo, Gilbert, Alberto Puccini, Joanne Xiu, Richard M. Goldberg, Axel Grothey, Anthony F. Shields, Sukeshi Patel Arora i in. "Molecular profile of BRCA-mutated biliary tract cancers". ESMO Open 5, nr 3 (czerwiec 2020): e000682. http://dx.doi.org/10.1136/esmoopen-2020-000682.
Pełny tekst źródłaHart, Lowell L., Kai Treuner, Li Ma, Jenna Wong, Catherine A. Schnabel i James Andrew Reeves. "Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for PARP inhibitors." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e15080-e15080. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15080.
Pełny tekst źródła